Viewing Study NCT07483567


Ignite Creation Date: 2026-03-26 @ 3:18 PM
Ignite Modification Date: 2026-03-31 @ 7:26 AM
Study NCT ID: NCT07483567
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-19
First Post: 2026-03-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None CLDN18.2 Positive View
None Primary Gastric Adenocarcinoma View
None Gastroesophageal Junction Adenocarcinoma View
Keywords: